cope
nvest
🇮🇹
Protagonist Therapeutics, Inc.
PTGX
· Healthcare
$146.49
Capitalizzazione: 9.48B USD
Rendimento da dividendo: —
Advance
È un buon momento per comprare Protagonist Therapeutics, Inc.? Chiedi a Copenvest AI
Ottieni un'analisi Advance con AI su timing, rischio e cosa fanno gli investitori tracciati.
Chiedi a Copenvest AI
→
Caricamento grafico…
Notizie
Ultime notizie su questo titolo
Insider Monkey
4 set 2026, 16:14
MIMRYLO Approval Triggered $275M Payments for Protagonist (PTGX). Are Royalties the Better Commercial Model?
ACCESS Newswire
2 set 2026, 11:05
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026
Simply Wall St.
1 set 2026, 23:07
Protagonist Therapeutics (PTGX) Stock Could Be Overvalued Following FDA Approval News
Simply Wall St.
1 set 2026, 08:13
Protagonist Therapeutics (PTGX) Could Be 63% Below Fair Value After Investor Update Call
Simply Wall St.
1 set 2026, 05:05
Why Is Protagonist Therapeutics (PTGX) In Focus After MIMRYLO FDA Approval?
